Pfizer Inc. (BMV:PFE)
Mexico
· Delayed Price · Currency is MXN 479.99
+6.65 (1.40%)
At close: Jul 4, 2025, 2:00 PM CST
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Oncology | 15.61B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Oncology Growth | 21.68% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | 81.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | 40.35% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Business Innovation (Pfizer CentreOne) | 1.15B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Business Innovation (Pfizer CentreOne) Growth | -6.22% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Primary Care | 30.14B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Primary Care Growth | 8.20% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Specialty Care | 16.65B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Specialty Care Growth | 10.40% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | 81.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | 40.35% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | 81.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | 40.35% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Other | 24.94B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
United States | 38.69B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
United States Growth | 29.72% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Developed Markets | 16.06B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Developed Markets Growth | -13.19% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Emerging Markets Revenue (Post-FY2023 Reporting) | 8.88B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Emerging Markets Revenue (Post-FY2023 Reporting) Growth | 4.12% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | 24.94B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Developed Europe | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Developed Europe Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Developed Rest of World | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Developed Rest of World Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Emerging Markets | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Emerging Markets Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | 24.94B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Other | -12.73B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | 32.22% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | -12.73B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | 32.22% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Global Pharmaceuticals Business (Biopharma) Earnings | 28.14B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Global Pharmaceuticals Business (Biopharma) Earnings Growth | -6.78% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Business Activities Earnings | -7.38B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Business Activities Earnings Growth | -29.25% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | -12.73B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | 32.22% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Prevnar Revenue | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Prevnar Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Xeljanz Revenue | 1.17B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Xeljanz Revenue Growth | -33.57% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Vaccines Revenue | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Vaccines Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Ibrance Revenue | 4.37B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Ibrance Revenue Growth | -8.02% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Internal Medicine Revenue | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Internal Medicine Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Inflammation & Immunology Revenue | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Inflammation & Immunology Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rare Disease Revenue | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rare Disease Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Eliquis Alliance Revenue and Direct Sales | 7.37B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Eliquis Alliance Revenue and Direct Sales Growth | 4.88% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Vyndaqel Family Revenue | 5.45B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Vyndaqel Family Revenue Growth | 53.76% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Hospital Revenue | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Hospital Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Comirnaty Direct Sales and Alliance Revenue | 5.35B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Comirnaty Direct Sales and Alliance Revenue Growth | -34.60% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Paxlovid Revenue | 5.72B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Paxlovid Revenue Growth | -652.58% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Prevnar Family Revenue | 6.41B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Prevnar Family Revenue Growth | -3.17% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Nurtec ODT/Vydura Revenue | 1.26B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Nurtec ODT/Vydura Revenue Growth | 41.81% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Abrysvo Revenue | 755.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|